With +4 years of experience with anti-NGF mAb OA therapies in Europe, and nearly 28M doses of Librela and 9M doses of Solensia delivered globally,¹ together we are making a difference for cats and dogs around the world!
Join us on a 3-part journey as we explore the impact these innovative therapies have made on pets, their owners, and veterinary health teams across the UK.
Full Episodes
Highlight Clips
Learn about the new era in OA pain control.
LIBRELA IMPORTANT SAFETY INFORMATION:
Librela is for use in dogs only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid self-injection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. Librela should not be used in breeding, pregnant, or lactating dogs. Librela should not be administered to dogs with known hypersensitivity to bedinvetmab. Adverse events reported post-approval include ataxia (lack of balance/ coordination), anorexia (loss of appetite), lethargy (tiredness), emesis (vomiting), and polydipsia (increased drinking). The most common adverse events reported in a clinical study were urinary tract infections, bacterial skin infections and dermatitis (skin irritation/inflammation). For complete safety information, refer to the full prescribing information at LibrelaPI.com.
SOLENSIA IMPORTANT SAFETY INFORMATION:
For use in cats only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid self-injection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. SOLENSIA should not be used in breeding cats or in pregnant or lactating queens. SOLENSIA should not be administered to cats with known hypersensitivity to frunevetmab. The most common adverse events reported in a clinical study were vomiting and injection site pain. Solensia may be associated with scabbing of the head and neck, dermatitis, and pruritus. See full Prescribing Information at
SolensiaPI.com.